unknown
Stage
About
Alp develops a platform that uses human tonsil organoid technology combined with protein AI to predict, validate, and reduce immunogenicity risk in therapeutic antibodies before clinical development.
Explore Alp's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.